GHRS
GH Research Plc · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website ghres.com
- Employees(FY) 32
- ISIN IE000GID8VI0
Performance
+5.09%
1W
+14.65%
1M
+57.5%
3M
+72.13%
6M
+117.24%
YTD
+13.92%
1Y
Profile
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Technical Analysis of GHRS 2024-05-10
Overview:
In analyzing the technical indicators for GHRS over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average has been consistently above the closin...
Recent News & Updates
- 2023-01-08 18:30
- 2022-11-20 23:22
7 Short-Squeeze Stocks for Bold Contrarians to Consider(Yahoo Finance)
- 2022-11-09 18:05
- 2022-09-13 21:55
- 2022-08-30 03:02
7 Psychedelics Stocks to Buy for a Big Drug Boom(Yahoo Finance)
- 2022-08-28 21:55
- 2022-08-22 19:00
- 2022-05-17 19:00
- 2022-03-27 19:04
- 2022-03-23 23:48
- 2021-12-05 18:10
- 2021-12-05 18:00
- 2021-10-26 16:50
- 2021-09-24 22:07
- 2021-09-23 05:25
- 2021-07-02 04:20
- 2021-06-25 01:23
Page 2 of 2
previousnext